European Union - English - EMA (European Medicines Agency)

camurus ab - buprenorphine - opioid-related disorders - other nervous system drugs - treatment of opioid dependence within a framework of medical, social and psychological treatment. treatment is intended for use in adults and adolescents aged 16 years or over.

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

camurus ab, sweden - buprenorphine - solution for injection - 24 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

camurus ab, sweden - buprenorphine - solution for injection - 16 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

camurus ab, sweden - buprenorphine - solution for injection - 8 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

camurus ab, sweden - buprenorphine - solution for injection - 64 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

camurus ab, sweden - buprenorphine - solution for injection - 32 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

camurus ab, sweden - buprenorphine - solution for injection - 128 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

camurus ab, sweden - buprenorphine - solution for injection - 96 mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

camurus ab -

Australia - English - Department of Health (Therapeutic Goods Administration)

camurus pty ltd - buprenorphine, quantity: 128 mg - injection, solution - excipient ingredients: n-methyl-2-pyrrolidone; phosphatidyl choline; glyceryl dioleate; nitrogen - buvidal monthly is indicated for maintenance treatment of opioid dependence with prior stabilisation on buvidal weekly or sublingual buprenorphine or buprenorphine/naloxone within a framework of medical, social and psychological support.